Clinical Trial Detail

NCT ID NCT01455389
Title FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Genprex, Inc.
Indications

lung non-small cell carcinoma

Therapies

DOTAP:chol-Fus1

Erlotinib

Diphenhydramine

Dexamethasone

Age Groups: senior adult

No variant requirements are available.